Lemildipine
Based on 1 Customer Validation
Lemildipine is a new dihydropyridine calcium entry blocker.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.58%
- CAS. Nr.: 94739-29-4
- Formel: C20H22Cl2N2O6
- Molecular Weight:457.30
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Calcium entry[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 94739-29-4
-
Appearance Solid
-
Molecular Weight 457.30
-
Formel C20H22Cl2N2O6
-
Color White to yellow
-
SMILES
O=C(C1=C(COC(N)=O)NC(C)=C(C(OC)=O)C1C2=CC=CC(Cl)=C2Cl)OC(C)C
-
Synonyms
NB-818; NPK-1886
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (218.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
Gerbils[1]
Male Mongolian gerbils, weighing 50-80g, are used in this experiment. Lemildipine (3 mg/kg) or vehicle is administered intraperitoneally just after the recirculation. At 1, 2 or 4 weeks after ischemia, the animals are sacrificed, and the protective effect of Lemildipine (NB-818) is examined.
Mice and Rats[2]
Normal Wistar rats (NWR) and hypertensive model rats (spontaneously hypertensive rats (SHR), renal hypertensive rats (RHR) and DOCA-saline-induced hypertensive rats (DOC-Na-R)) of the male sex, weighing from 250 to 350 g, are used. Oral administration of Lemildipine in doses of 3, 10, 30 mg/kg for normal Wistar rats (NWR). Lethal dose of Lemildipine and Nifedipine is determined by the Litchfield-Wilcoxon method from the data of experiments using healthy mice and rats. Mice (male and female) weighing 20±2 g and male rats weighing from 150 to 220 g are used. These two kinds of animals are fed on solid food (Crea, CA-1) and water ad lib. The animal room temperature and humidity are controlled at 22±2°C and 55±5%, respecttively. No food except water is administered 24 hr before starting the experiments for oral administration of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kamei K, et al. Effect of a new calcium entry blocker, NB-818, on delayed neuronal death in the ischemic gerbil hippocampus. Jpn J Pharmacol. 1991 Jul;56(3):279-86. [Content Brief]
[2]. Nagura J, et al. Cardiovascular effects of NPK-1886, a new dihydropyridine compound with calcium entry blocking activity. Jpn J Pharmacol. 1986 Mar;40(3):399-409. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1867 mL | 10.9337 mL | 21.8675 mL | 54.6687 mL |
| 5 mM | 0.4373 mL | 2.1867 mL | 4.3735 mL | 10.9337 mL | |
| 10 mM | 0.2187 mL | 1.0934 mL | 2.1867 mL | 5.4669 mL | |
| 15 mM | 0.1458 mL | 0.7289 mL | 1.4578 mL | 3.6446 mL | |
| 20 mM | 0.1093 mL | 0.5467 mL | 1.0934 mL | 2.7334 mL | |
| 25 mM | 0.0875 mL | 0.4373 mL | 0.8747 mL | 2.1867 mL | |
| 30 mM | 0.0729 mL | 0.3645 mL | 0.7289 mL | 1.8223 mL | |
| 40 mM | 0.0547 mL | 0.2733 mL | 0.5467 mL | 1.3667 mL | |
| 50 mM | 0.0437 mL | 0.2187 mL | 0.4373 mL | 1.0934 mL | |
| 60 mM | 0.0364 mL | 0.1822 mL | 0.3645 mL | 0.9111 mL | |
| 80 mM | 0.0273 mL | 0.1367 mL | 0.2733 mL | 0.6834 mL | |
| 100 mM | 0.0219 mL | 0.1093 mL | 0.2187 mL | 0.5467 mL |